The Center of Registers, in cooperation with the Ministry of Health, implemented the project of creation and implementation of the information system of the Lithuanian National E-Health Contact Center (LNKC IS). LNKC operates in the common European Union health data exchange infrastructure, which ensures cross-border e-mail of EU residents. exchange of prescriptions and patient summaries. The created functionality allows Lithuania to exchange e-mail prescription data throughout the EU, and also allows EU citizens who have arrived in Lithuania with their e-mail to purchase the medicines they need by prescription in our country.
When the new service is launched, some pharmacies in foreign countries may not be able to immediately successfully connect to cross-border e-mails. prescription system, therefore it is recommended that before going to buy medicines in Latvia or Poland, you should inquire about the possibility of using the Lithuanian e-mail address of the specific pharmacy by phone. recipe.
“By opening the opportunity for Lithuanian residents to purchase prescription drugs in foreign countries, we are taking an important step towards an even stronger European health union.
Residents of Lithuania who use prescription drugs, who work, study or travel in EU countries, will not need to carry a paper prescription with them, because the electronic prescription issued in Lithuania will be visible and valid in the pharmacy of a foreign country.
Also, Lithuanian citizens living abroad and receiving health services will have the opportunity to purchase prescription drugs in Lithuanian pharmacies when visiting Lithuania. This will reduce inconvenience for travelers and reduce the risk of medication discontinuation. This European-scale project is implemented in stages, starting with two neighboring countries – Latvia and Poland, but later the list of EU countries will continue to be consistently expanded,” says Deputy Minister of Health Oleg Niakšu.
All reimbursable and non-reimbursable prescription drugs can be purchased abroad, except for narcotic, extemporaneous, and branded medicinal products.
Until 2025 March 31 it is not possible to purchase medicinal products in the pharmaceutical form of inhalable medicinal products, powders, powders for injection or infusion solution, or medicinal products in liquid and soft pharmaceutical form. Medicines in these pharmaceutical forms, as well as compensable medical aids, must still be issued with paper prescriptions.
According to Diana Vilytė, Director of Service Management of the Registry Center, this new functionality will open up even more opportunities to take advantage of the benefits of digital services.
“Every month in Lithuania, more than 1.5 million email prescriptions, pharmacies in the country issue a similar amount of prescription drugs to residents. In the field of digitization of health services, we have advanced further than many EU countries. This new functionality will not only allow residents of the country to purchase prescription drugs abroad, but citizens of foreign countries who have arrived here will be able to do the same in Lithuania”, says D. Vilytė.
The beginning is with the neighboring countries
The first EU country with which Lithuania started to exchange e-mail according to the recipes, there is neighboring Latvia, and from next week cooperation with Poland will also begin.
“In Lithuania, all major pharmacy chains of the country contribute to this project, so citizens of Latvia or Poland should not have any difficulties in purchasing prescription drugs in our country. The vast majority of Latvian and Polish pharmacies also participate in the project, and very soon the list of cooperating countries will be supplemented by neighboring Estonia, as well as Spain and Finland, which are popular with Lithuanian tourists. We hope that in this way compatriots visiting abroad will not have difficulties in purchasing prescription drugs”, says D. Vilytė.
It is expected that the new opportunities will not only better ensure the health care needs of Lithuanian citizens when traveling in the EU, but will also raise the level of health care services provided to European citizens in Lithuania.
The project was implemented with EU and state budget funds, the technical solution of the Registry Center orders for 0.5 million. implemented by the company “Novian Systems”.
According to the Center of Registers, in 2023, about 20 million were issued in Lithuania. email of prescriptions, about 18 million were issued in pharmacies with them. prescription drugs.
Medicines prescribed by a doctor in Lithuania can be bought in 2 other countries
How to Prevent Pneumonia: Tips for a Non-Smoking Lifestyle and Vaccination
REPUBLIKA.CO.ID, JAKARTA – A non-smoking lifestyle is said to prevent pneumonia. An internal medicine specialist at the Central General Hospital (RSUP) Dr. Sardjito, Dr. Taufik Indrawan said the smallpox or as the public knows the smallpox inflammation is caused by infection.
“So no smoking, okay smoke current and modern cigarettes,” said Taufik in “Sleeping on the floor often makes your lungs wet, is it true?” which was broadcast by the Ministry of Health in Jakarta, Thursday (2/5/ 2024).
Dr Taufik said the risk of pneumonia is higher in children and the elderly, especially those with chronic diseases such as chronic kidney disease, chronic heart disease and diabetes. “Among the causes of death in children are pneumonia and diarrhea. It is also the same in old people or elderly people. Among the most common causes of diseases in the elderly is pneumonia,” he said.
Taufik said the next step to prevent pneumonia is to avoid pollution. If you have to because the work environment is contaminated, you must wear a mask.
He explained that pneumonia is caused by pollution, bacteria, viruses and fungi. In addition, he said, the symptoms that may appear are caused by the immune system trying to attack the pathogen, namely cough, fever, and if not treated, shortness of breath.
“A lot of pneumonia is caused by upper respiratory tract infections, so it starts with the common cold first, but because it’s not treated, the germs then go down into the lungs , into the lower respiratory tract. Until that becomes a plague. he said.
The next step to preventing pneumonia is to maintain the immune system, by exercising and eating nutritious food and getting vaccinated. The two recommended vaccines, he said, are the pneumonia vaccine and the flu vaccine.
He said that the vaccine is very effective in preventing pneumonia. However, the pneumonia vaccine must be taken every five years, while the flu vaccine lasts only once a year, because the virus changes so quickly.
source: Inter
2024-05-02 12:15:32
#Doctor #Smoking #Prevent #Pneumonia #republic #online
Related posts:
How to Prevent Pneumonia: Tips for a Non-Smoking Lifestyle and Vaccination
Cardiac Adverse Events and Remdesivir in COVID-19 Patients: Discovery Trial Safety Analysis
2024-05-02 10:48:20
(1) Terzić V (1,2), Miantezila Basilua J (1,2), Billard N (3), de Gastines L (1,2), Belhadi D (3,6), Fougerou-Leurent C (4), Peiffer- Smadja N (5,6), Mercier N (1,2), Delmas C (7), Ferrane A (7), Dechanet A (3), Poissy J (8), Espérou H (7), Ader F (9 ) ), Hites M (10), Andrejak C (11), Greil R (12), Paiva JA (13), Staub T (14), Tacconelli E (15), Burdet C (3), Costagliola D (16) , Mentré F (3,6), Yazdanpanah Y (3,5,17), Diallo A (1,2) and the study group Discovery. Cardiac adverse events and remdesivir in hospitalized patients with Coronavirus Disease 2019 (COVID-19): A post hoc safety analysis of the randomized Discovery trial.
Clin Infect Dis 2024 Mar 29:ciae170.
(2) Gottlieb RL and Kalil AC. True detection of COVID-19 disease burden versus speculated antiviral cardiovascular risk requires a control group. Clin Infect Dis 2024 Mar 29:ciae172.
(3) https://cordis.europa.eu/project/id/101015736
Funded by Europe (The EU’s Horizon 2020 research and innovation program under grant agreement no. 101015736), Discovery is now research axis 1 in the EU-RESPONSE project (European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases, which brings together 22 partners (clinics, hospitals, universities, etc.) from 13 countries in the EU, Norway, Switzerland, Luxembourg and Turkey.
(4) Ader F, et al. Final results of the Discovery study of remdesivir for patients hospitalized with COVID-19. Lancet Infect Dis 2022;22(6):764-765.
(5) Gottlieb RL, et al. Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2022;386(4):305-315.
(6) Amstutz A, et al. Effects of remdesivir in patients hospitalized with COVID-19: a systematic review and individual patient data meta-analysis of randomized controlled trials. Lancet Respir Med 2023; 11(5):453-464.
1714647901
#Discovery #Remdesivir #expose #hospitalized #patients #Covid19 #increased #risk #cardiac #effects
Related posts:
Cardiac Adverse Events and Remdesivir in COVID-19 Patients: Discovery Trial Safety Analysis